IRVINE, Calif.--(BUSINESS WIRE)--Oct 21, 2026--
Immunis, Inc., a clinical-stage biotechnology company developing first-in-class multi-active biologics for muscle health and healthy aging, today announced that it has been selected to receive the Grand Prize in the National Academy of Medicine’s (NAM) Healthy Longevity Global Competition, a global initiative designed to accelerate breakthroughs that extend human healthspan and improve physical, cognitive and social well-being throughout life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021720676/en/
From 2020 to 2025, NAM and its global partners awarded 720 Catalyst Awards totaling more than $36 million to innovators across more than 50 countries and territories. The 2026 Grand Prize was open exclusively to those Catalyst Award recipients and recognizes the groups with the most promising innovation in healthy longevity.
Immunis was recognized for “IMM01-STEM: A First-in-Class Regenerative Biologic Restoring Muscle Function, Metabolism, and Quality of Life in Aging Adults.” The investigational IMM01-STEM therapy is a multi-active biologic that can address the interconnected biological processes underlying age-related muscle and metabolic decline.
Unlike approaches that target a single pathway, IMM01-STEM contains multiple naturally occurring factors designed to act across signaling pathways involved in immune regulation, tissue repair and muscle regeneration. Immunis’ pipeline will investigate IMM01-STEM as both a stand-alone muscle therapy and as an adjunct therapy in combination with GLP-1 therapies to preserve and restore lean mass while enhancing fat loss.
“We are deeply honored to receive this recognition from the National Academy of Medicine,” said Dr. Tom Lane, Chief Science Officer of Immunis. “Healthy longevity is about preserving the strength and function that improve a patient’s quality of life,” said Dr. Lane. “This Grand Prize provides our team with means to continue our clinical research and, eventually, the opportunity to help millions of people.”
Immunis has advanced IMM01-STEM into a randomized Phase 2 clinical trial, with evidence to date demonstrating improvements in measures of muscle function, metabolism and quality of life in aging adults. Blood protein analyses have also identified coordinated changes across immune cell signaling, tissue repair and muscle regeneration pathways. No severe adverse events attributed to IMM01-STEM have been reported to date.
Published preclinical research further supports the therapeutic’s potential, demonstrating improvements across measures including lean mass, fat mass, muscle fiber quality, physical activity, glucose handling and liver health.
The recognition comes as age-related loss of muscle and metabolic function is increasingly emerging as a critical challenge to healthy longevity. By targeting multiple interconnected pathways rather than a single mechanism, Immunis is developing IMM01-STEM with the goal of preserving the strength, mobility and metabolic health that allow people to remain active and independent as they age.
Immunis thanks the National Academy of Medicine for this distinguished honor and celebrates with the other awardees on the culmination of a 7-year long search for the greatest innovations in healthy longevity.
About Immunis
Immunis is a clinical-stage biotechnology company developing first-in-class multi-active biologics designed to restore function lost through aging and disease. Leveraging the body’s innate repair biology, Immunis’ proprietary secretome platform targets multiple pathways simultaneously to improve muscle health, metabolic function, and overall healthspan. The company’s lead investigational therapy, IMM01-STEM, is being evaluated as a potential treatment for sarcopenia and other age-related conditions, with the vision of helping people live healthier, stronger, and more independent lives for longer.
Immunis is the proud winner of the National Academy of Medicine's Healthy Longevity Global Grand Prize Competition
NEW YORK (AP) — NFL Commissioner Roger Goodell said Wednesday he has a high comfort level in the New Orleans Saints and Pittsburgh Steelers safely playing in Paris on Sunday in light of the civil unrest that could include more protests this weekend in the capital and elsewhere around France.
Goodell at the end of the annual fall owners meeting said he had spoken with U.S. Secretary of State Marco Rubio and that officials are in touch with Parisian and French authorities.
“We’ve made all the preparations,” Goodell said. “Protests are not unusual in France, as you know, and that’s something that we will be aware of and make sure that the appropriate arrangements are made.”
Saints general manager Mickey Loomis said in Versailles that the team’s plans have not been affected by the situation. They have been in France since Monday after flying directly from the New York area after playing at the Giants, while the Steelers are set to travel Thursday night.
“We’re continuing to make sure we have all the available information, make sure the appropriate steps are being made,” he said. "We’re guests in the country. We’re going to be good guests, and we’re going to do our thing. And I’m confident they’re going to do theirs. We look forward to it, and I’m leaving shortly to go myself."
New Orleans safety Justin Reid said he and other players are not worried.
Goodell defended the presence of Steve Tisch of the Giants and Jed York of the San Francisco 49ers, each of whom was in attendance for the two-day meeting.
Tisch remains executive vice president and chairman of the board after he and his siblings transferred their stakes to their children earlier this year. Tisch's name was mentioned more than 400 times in Jeffrey Epstein files released in January by the U.S. Justice Department.
After pledging at the Super Bowl there would be a review of Tisch's association with Epstein, Goodell said Wednesday, “Everything we’ve looked at, we understand and I think we’re comfortable with him participating as the Giants suggest.”
Asked if the investigation was ongoing, Goodell said: “I think always we’ll look to see if there’s any new information. We’ll look at it, and we’ll evaluate that.”
Tisch said he knew Epstein but denied going to his island.
York returned from his six-game suspension for violating the NFL's personal conduct policy. He was arrested in a prostitution sting in Ohio in August and pleaded no contest to two misdemeanors but was still punished by the league.
“We went through a full process, obviously, to understand the facts, to understand the issues,” Goodell said. “(We) looked at it under the context of our personal conduct policy, which applies to owners, commissioners, everybody else, players. And it’s something we feel strongly about. I think we need to represent ourselves and our organizations properly. We saw a violation, and we’ve dealt with it from a discipline standpoint. That’s concluded now, and so he’ll be back representing the 49ers.”
Executive VP of football operations Troy Vincent said the two officials who were suspended for their interactions with players earlier this season “crossed the line.” Line judge Jeff Seeman was banned two games for swearing at Arizona tight end Trey McBride, and referee Adrian Hill one game for yelling at Eric Wilson and pointing for him to get away after the Vikings linebacker tried to help him to his feet after a collision knocked him over.
Vincent called the reactions unacceptable, and Goodell said it was a matter of sportsmanship and professional conduct.
“We do want accountability of our officials, but we also want respect between the participants,” Goodell said. “It’s not just player to players. Officials play an important role out there, and they need to be held to the highest standards.”
AP Sports Writer Ken Maguire in Versailles, France, contributed to this report.
See AP’s full NFL coverage here
NFL commissioner Roger Goodell speaks during a news conference at the NFL owners' meetings Wednesday, Oct. 21, 2026, in New York. (AP Photo/Yuki Iwamura)
Executive Vice President and General Manager of the New Orleans Saints Mickey Loomis speaks during a press conference after an NFL football practice session in Versailles near Paris, Wednesday, Oct. 21, 2026. (AP Photo/Aurelien Morissard)
New Orleans Saints wide receiver Chris Olave (12) during an NFL football practice session in Versailles near Paris, Wednesday, Oct. 21, 2026. (AP Photo/Aurelien Morissard)
New Orleans Saints team during an NFL football practice session in Versailles near Paris, Wednesday, Oct. 21, 2026. (AP Photo/Aurelien Morissard)
